| Primary |
| Hiv Infection |
28.2% |
| Antiretroviral Therapy |
20.5% |
| Drug Use For Unknown Indication |
12.8% |
| Rectal Cancer |
10.3% |
| Hepatitis C |
7.7% |
| Product Used For Unknown Indication |
7.7% |
| Chronic Obstructive Pulmonary Disease |
5.1% |
| Liposarcoma |
5.1% |
| Metastases To Lung |
2.6% |
|
| Respiratory Failure |
16.7% |
| Cholangitis |
8.3% |
| Hepatic Fibrosis |
8.3% |
| Herpes Simplex |
8.3% |
| Intra-uterine Death |
8.3% |
| Nephrolithiasis |
8.3% |
| Nephropathy Toxic |
8.3% |
| Pancreatitis |
8.3% |
| Threatened Labour |
8.3% |
| Weight Decreased |
8.3% |
| Wound Dehiscence |
8.3% |
|
| Secondary |
| Hiv Infection |
60.0% |
| Drug Use For Unknown Indication |
11.4% |
| Antiretroviral Therapy |
8.9% |
| Drug Exposure During Pregnancy |
4.8% |
| Acquired Immunodeficiency Syndrome |
1.9% |
| Prophylaxis |
1.7% |
| Mycobacterium Avium Complex Infection |
1.5% |
| Antiviral Prophylaxis |
1.4% |
| Hepatitis C |
1.3% |
| Prophylaxis Against Transplant Rejection |
1.1% |
| Insomnia |
0.9% |
| Prophylaxis Against Hiv Infection |
0.9% |
| Product Used For Unknown Indication |
0.8% |
| Antifungal Prophylaxis |
0.7% |
| Human Immunodeficiency Virus Transmission |
0.7% |
| Cytomegalovirus Infection |
0.6% |
| Hypertension |
0.4% |
| Nephrotic Syndrome |
0.4% |
| Antibiotic Prophylaxis |
0.3% |
| Encephalopathy |
0.3% |
|
| Pregnancy |
11.4% |
| Vomiting |
7.9% |
| White Blood Cell Count Decreased |
7.0% |
| Osteonecrosis |
6.6% |
| Drug Exposure During Pregnancy |
6.1% |
| Hypospadias |
6.1% |
| Portal Hypertension |
6.1% |
| Premature Baby |
5.2% |
| Sick Sinus Syndrome |
4.4% |
| Urine Colour Abnormal |
4.4% |
| Myocardial Infarction |
3.9% |
| Neutrophil Count Decreased |
3.9% |
| Progressive Multifocal Leukoencephalopathy |
3.9% |
| Transplant Rejection |
3.9% |
| Varices Oesophageal |
3.9% |
| Joint Dislocation |
3.5% |
| Nodular Regenerative Hyperplasia |
3.5% |
| Encephalopathy |
3.1% |
| Hydrocele |
2.6% |
| Lymphoma |
2.6% |
|
| Concomitant |
| Hiv Infection |
67.8% |
| Drug Use For Unknown Indication |
5.4% |
| Drug Exposure During Pregnancy |
4.6% |
| Product Used For Unknown Indication |
3.5% |
| Factor Viii Deficiency |
3.1% |
| Antibiotic Prophylaxis |
2.2% |
| Hepatitis C |
2.0% |
| Diarrhoea |
1.5% |
| Systemic Antiviral Treatment |
1.3% |
| Antiretroviral Therapy |
1.1% |
| Gastritis |
1.1% |
| Human Immunodeficiency Virus Transmission |
1.1% |
| Upper Respiratory Tract Infection |
1.1% |
| Antifungal Prophylaxis |
0.8% |
| Convulsion |
0.8% |
| Mycobacterium Avium Complex Infection |
0.7% |
| Pneumonia |
0.7% |
| Tuberculosis Skin Test Positive |
0.7% |
| Acquired Immunodeficiency Syndrome |
0.4% |
| Syphilis |
0.4% |
|
| Weight Decreased |
14.3% |
| Drug Exposure During Pregnancy |
13.0% |
| Ventricular Septal Defect |
11.7% |
| Stillbirth |
5.2% |
| Unevaluable Event |
5.2% |
| Vomiting |
5.2% |
| Factor Viii Inhibition |
3.9% |
| Glucose-6-phosphate Dehydrogenase Deficiency |
3.9% |
| Liver Disorder |
3.9% |
| Mitochondrial Cytopathy |
3.9% |
| Neonatal Respiratory Distress Syndrome |
3.9% |
| Oesophageal Candidiasis |
3.9% |
| Pregnancy |
3.9% |
| Congenital Hip Deformity |
2.6% |
| Genitalia External Ambiguous |
2.6% |
| Hepatitis C |
2.6% |
| Human Anti-mouse Antibody Positive |
2.6% |
| Hyperglycaemia |
2.6% |
| Hypertension |
2.6% |
| Live Birth |
2.6% |
|
| Interacting |
| Antiretroviral Therapy |
58.7% |
| Hiv Infection |
17.4% |
| Drug Use For Unknown Indication |
6.5% |
| Chronic Obstructive Pulmonary Disease |
4.3% |
| Antibiotic Prophylaxis |
2.2% |
| Complex Partial Seizures |
2.2% |
| Immune Reconstitution Syndrome |
2.2% |
| Oral Candidiasis |
2.2% |
| Organic Erectile Dysfunction |
2.2% |
| Product Used For Unknown Indication |
2.2% |
|
| Drug Interaction |
28.6% |
| Herpes Simplex |
14.3% |
| Pain In Extremity |
14.3% |
| Parotid Gland Enlargement |
14.3% |
| Rash Pruritic |
14.3% |
| Viral Load Increased |
14.3% |
|
